In conclusion, we recommend that patients with a younger age, distant metastasis, a lower tumor grading, a smaller tumor size and higher preoperative CA19-9 and CEA levels should have regular follow-ups, and the progression of the disease should be closely monitored in these patients. This evidence concerns the gene CEACAM5 and neoplasm.